Skip to main content
Top
Published in: BMC Infectious Diseases 1/2016

Open Access 01-12-2016 | Research article

The effect of surgery on the outcome of treatment for multidrug-resistant tuberculosis: a systematic review and meta-analysis

Authors: Rebecca C. Harris, Mishal S. Khan, Laura J. Martin, Victoria Allen, David A. J. Moore, Katherine Fielding, Louis Grandjean, the LSHTM MDR-TB surgery systematic review group

Published in: BMC Infectious Diseases | Issue 1/2016

Login to get access

Abstract

Background

In 2014 only 50 % of multidrug-resistant tuberculosis (MDR-TB) patients achieved a successful treatment outcome. With limited options for medical treatment, surgery has re-emerged as an adjuvant therapeutic strategy. We conducted a systematic review and meta-analysis to assess the evidence for the effect of surgery as an adjunct to chemotherapy on outcomes of adults treated for MDR-TB.

Methods

Databases and grey literature sources were searched using terms incorporating surgery and MDR-TB. No language or publication type limits were applied. Articles published pre-1990, without a comparator group, or reporting <10 surgical participants were excluded. Two-stage sifting in duplicate was employed. Data on WHO-defined treatment outcomes were abstracted into a standardised database. Study-level risk of bias was evaluated using standardised tools. Outcome-level evidence quality was assessed using GRADE. Forest plots were generated, random effects meta-analysis conducted, and heterogeneity assessed using the I2 statistic.

Results

Of 1024 unique citations identified, 62 were selected for full-text review and 15 retained for inclusion. A further four articles were included after bibliography/citation searching, and one additional unpublished manuscript was identified, giving 20 articles for final inclusion. Six were meta-analyses/systematic reviews and 14 were primary research articles (observational studies).
From the 14 primary research articles, a successful outcome (cured/treatment completed) was reported for 81.9 % (371/453) and 59.7 % (1197/2006) in the surgical and non-surgical group respectively, giving a summary odds ratio of 2.62 (95 % confidence interval 1.94–3.54). Loss to follow-up and treatment failure were lower in the surgery group (both p = 0.01). Overall GRADE quality of evidence for all outcomes considered was “very low”.

Conclusions

This meta-analysis suggests that surgery as an adjunct to chemotherapy is associated with improved treatment outcomes in MDR-TB patients. However, inherent limitations in observational study design, insufficient reporting, and lack of adjustment for confounders, led to grading of the evidence as very low quality. Data on rationale for surgical referral, subsequent outcomes and resource-limited settings are scarce, precluding evidence-based recommendations on the suitability of surgery by patient characteristics or setting. It is hoped that highlighted methodological and reporting gaps will encourage improved design and reporting of future surgical studies for MDR-TB.
Appendix
Available only for authorised users
Literature
8.
go back to reference Iseman MD, Madsen L, Goble M, Pomerantz M. Surgical intervention in the treatment of pulmonary disease caused by drug-resistant Mycobacterium tuberculosis. Am Rev Respir Dis. 1990;141:623–5.CrossRefPubMed Iseman MD, Madsen L, Goble M, Pomerantz M. Surgical intervention in the treatment of pulmonary disease caused by drug-resistant Mycobacterium tuberculosis. Am Rev Respir Dis. 1990;141:623–5.CrossRefPubMed
9.
go back to reference Kempker RR, Vashakidze S, Solomonia N, Dzidzikashvili N, Blumberg HM. Surgical treatment of drug-resistant tuberculosis. Lancet Infect Dis. 2012;12:157–66.CrossRefPubMedPubMedCentral Kempker RR, Vashakidze S, Solomonia N, Dzidzikashvili N, Blumberg HM. Surgical treatment of drug-resistant tuberculosis. Lancet Infect Dis. 2012;12:157–66.CrossRefPubMedPubMedCentral
10.
go back to reference Marrone MT, Venkataramanan V, Goodman M, Hill AC, Jereb JA, Mase SR. Surgical interventions for drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2013;17:6–16.CrossRefPubMed Marrone MT, Venkataramanan V, Goodman M, Hill AC, Jereb JA, Mase SR. Surgical interventions for drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2013;17:6–16.CrossRefPubMed
12.
go back to reference Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–9. W264.CrossRefPubMed Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–9. W264.CrossRefPubMed
14.
go back to reference Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. Accessed: 4 Sep 2015. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.​cochrane-handbook.​org. Accessed: 4 Sep 2015.
15.
go back to reference Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52(6):377–84.CrossRefPubMedPubMedCentral Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52(6):377–84.CrossRefPubMedPubMedCentral
16.
go back to reference West S, King V, Carey TS, Lohr KN, McKoy N, Sutton SF, Lux L. Systems to rate the strength of scientific evidence. In: AHRQ Evidence Report Summaries Rockville (MD) : Agency for Healthcare Research and Quality (US); 1998–2005. 2002. West S, King V, Carey TS, Lohr KN, McKoy N, Sutton SF, Lux L. Systems to rate the strength of scientific evidence. In: AHRQ Evidence Report Summaries Rockville (MD) : Agency for Healthcare Research and Quality (US); 1998–2005. 2002.
17.
go back to reference Higgins JPT: Green S. Cochrane handbook for systematic reviews of interventions version 5.1. 0. The Cochrane Collaboration 2011, 5(0). Higgins JPT: Green S. Cochrane handbook for systematic reviews of interventions version 5.1. 0. The Cochrane Collaboration 2011, 5(0).
20.
go back to reference Falzon D, Gandhi N, Migliori GB, Sotgiu G, Cox HS, Holtz TH, Hollm-Delgado MG, Keshavjee S, DeRiemer K, Centis R, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J. 2013;42(1):156–68.CrossRefPubMed Falzon D, Gandhi N, Migliori GB, Sotgiu G, Cox HS, Holtz TH, Hollm-Delgado MG, Keshavjee S, DeRiemer K, Centis R, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J. 2013;42(1):156–68.CrossRefPubMed
21.
go back to reference Fox GJ, Mitnick CD, Benedetti A, Chan ED, Becerra M, Chiang CY, Keshavjee S, Koh WJ, Shiraishi Y, Viiklepp P, et al. Surgery as an Adjunctive Treatment for Multidrug-Resistant Tuberculosis: An Individual Patient Data Metaanalysis. Clin Inf Dis. 2016;62:887–95. Fox GJ, Mitnick CD, Benedetti A, Chan ED, Becerra M, Chiang CY, Keshavjee S, Koh WJ, Shiraishi Y, Viiklepp P, et al. Surgery as an Adjunctive Treatment for Multidrug-Resistant Tuberculosis: An Individual Patient Data Metaanalysis. Clin Inf Dis. 2016;62:887–95.
22.
go back to reference Kwon YS, Kim YH, Suh GY, Chung MP, Kim H, Kwon OJ, Choi YS, Kim K, Kim J, Shim YM, et al. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clin Infect Dis. 2008;47:496–502.CrossRefPubMed Kwon YS, Kim YH, Suh GY, Chung MP, Kim H, Kwon OJ, Choi YS, Kim K, Kim J, Shim YM, et al. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clin Infect Dis. 2008;47:496–502.CrossRefPubMed
23.
go back to reference Leimane V, Riekstina V, Holtz TH, Zarovska E, Skripconoka V, Thorpe LE, Laserson KF, Wells CD. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet. 2005;365:318–26.CrossRefPubMed Leimane V, Riekstina V, Holtz TH, Zarovska E, Skripconoka V, Thorpe LE, Laserson KF, Wells CD. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet. 2005;365:318–26.CrossRefPubMed
24.
go back to reference Mitnick CD, Shin SS, Seung KJ, Rich ML, Atwood SS, Furin JJ, Fitzmaurice GM, Alcantara Viru FA, Appleton SC, Bayona JN, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Eng J Med. 2008;359:563–74.CrossRef Mitnick CD, Shin SS, Seung KJ, Rich ML, Atwood SS, Furin JJ, Fitzmaurice GM, Alcantara Viru FA, Appleton SC, Bayona JN, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Eng J Med. 2008;359:563–74.CrossRef
25.
go back to reference Törün T, Tahaoğlu K, Ozmen I, Sevim T, Ataç G, Kir A, Güngör G, Bölükbaşi Y, Maden E. The role of surgery and fluoroquinolones in the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2007;11(9):979–85.PubMed Törün T, Tahaoğlu K, Ozmen I, Sevim T, Ataç G, Kir A, Güngör G, Bölükbaşi Y, Maden E. The role of surgery and fluoroquinolones in the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2007;11(9):979–85.PubMed
26.
go back to reference Dravniece G, Cain KP, Holtz TH, Riekstina V, Leimane V, Zaleskis R. Adjunctive resectional lung surgery for extensively drug-resistant tuberculosis. Eur Respir J. 2009;34(1):180-3. Dravniece G, Cain KP, Holtz TH, Riekstina V, Leimane V, Zaleskis R. Adjunctive resectional lung surgery for extensively drug-resistant tuberculosis. Eur Respir J. 2009;34(1):180-3.
27.
go back to reference Sklyuev S, Levin A, Tcheimach E, Krasnov D. PC-658-02 Complex treatment approach for patients with destructive pulmonary tuberculosis by application of endobronchial valve. Int J Tuberc Lung Dis. 2013; 17(12, Supp.2):S329-330. Sklyuev S, Levin A, Tcheimach E, Krasnov D. PC-658-02 Complex treatment approach for patients with destructive pulmonary tuberculosis by application of endobronchial valve. Int J Tuberc Lung Dis. 2013; 17(12, Supp.2):S329-330.
28.
go back to reference Tahaoğlu K, Törün T, Sevim T, Ataç G, Kir A, Karasulu L, Ozmen I, Kapakli N. The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med. 2001;345:170–4.CrossRefPubMed Tahaoğlu K, Törün T, Sevim T, Ataç G, Kir A, Karasulu L, Ozmen I, Kapakli N. The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med. 2001;345:170–4.CrossRefPubMed
29.
go back to reference Shean KP, Willcox PA, Siwendu SN, Laserson KF, Gross L, Kammerer S, Wells CD, Holtz TH. Treatment outcome and follow-up of multidrug-resistant tuberculosis patients, West Coast/Winelands, South Africa, 1992–2002. Int J Tuberc Lung Dis. 2008;12(10):1182–9.PubMed Shean KP, Willcox PA, Siwendu SN, Laserson KF, Gross L, Kammerer S, Wells CD, Holtz TH. Treatment outcome and follow-up of multidrug-resistant tuberculosis patients, West Coast/Winelands, South Africa, 1992–2002. Int J Tuberc Lung Dis. 2008;12(10):1182–9.PubMed
30.
go back to reference Kwak N, Kim HR, Yoo CG, Kim YW, Han SK, Yim JJ. Changes in treatment outcomes of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2015;19:525–30.CrossRefPubMed Kwak N, Kim HR, Yoo CG, Kim YW, Han SK, Yim JJ. Changes in treatment outcomes of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2015;19:525–30.CrossRefPubMed
31.
go back to reference Kim H-R, Hwang SS, Kim HJ, Lee SM, Yoo C-G, Kim YW, Han SK, Shim Y-S, Yim J-J. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis. 2007;45(10):1290–5.CrossRefPubMed Kim H-R, Hwang SS, Kim HJ, Lee SM, Yoo C-G, Kim YW, Han SK, Shim Y-S, Yim J-J. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis. 2007;45(10):1290–5.CrossRefPubMed
32.
go back to reference Kim DH, Kim HJ, Park S-K, Kong S-J, Kim YS, Kim T-H, Kim EK, Lee KM, Lee SS, Park JS, et al. Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis. Am J Respir Crit Care Med. 2008;178:1075–82.CrossRefPubMed Kim DH, Kim HJ, Park S-K, Kong S-J, Kim YS, Kim T-H, Kim EK, Lee KM, Lee SS, Park JS, et al. Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis. Am J Respir Crit Care Med. 2008;178:1075–82.CrossRefPubMed
33.
go back to reference Keshavjee S, Gelmanova IY, Farmer PE, Mishustin SP, Strelis AK, Andreev YG, Pasechnikov AD, Atwood S, Mukherjee JS, Rich ML, et al. Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet. 2008;372:1403–9.CrossRefPubMed Keshavjee S, Gelmanova IY, Farmer PE, Mishustin SP, Strelis AK, Andreev YG, Pasechnikov AD, Atwood S, Mukherjee JS, Rich ML, et al. Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet. 2008;372:1403–9.CrossRefPubMed
34.
go back to reference Karagöz T, Yazicioğlu Moçin O, Pazarli P, Senol T, Yetiş Duman D, Duman G, Saltürk C, Unal O, Halezeroğlu S. The treatment results of patients with multidrug resistant tuberculosis and factors affecting treatment outcome. Tuberk Toraks. 2009;57:383–92.PubMed Karagöz T, Yazicioğlu Moçin O, Pazarli P, Senol T, Yetiş Duman D, Duman G, Saltürk C, Unal O, Halezeroğlu S. The treatment results of patients with multidrug resistant tuberculosis and factors affecting treatment outcome. Tuberk Toraks. 2009;57:383–92.PubMed
35.
go back to reference Gegia M, Kalandadze I, Kempker RR, Magee MJ, Blumberg HM. Adjunctive surgery improves treatment outcomes among patients with multidrug-resistant and extensively drug-resistant tuberculosis. Int J Infect Dis. 2012;16:e391–6.CrossRefPubMedPubMedCentral Gegia M, Kalandadze I, Kempker RR, Magee MJ, Blumberg HM. Adjunctive surgery improves treatment outcomes among patients with multidrug-resistant and extensively drug-resistant tuberculosis. Int J Infect Dis. 2012;16:e391–6.CrossRefPubMedPubMedCentral
36.
go back to reference Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, Becerra MC, Benedetti A, Burgos M, Centis R, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med. 2012;9(8):e1001300.CrossRefPubMedPubMedCentral Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, Becerra MC, Benedetti A, Burgos M, Centis R, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med. 2012;9(8):e1001300.CrossRefPubMedPubMedCentral
37.
go back to reference Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One. 2009;4:e6914.CrossRefPubMedPubMedCentral Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One. 2009;4:e6914.CrossRefPubMedPubMedCentral
38.
go back to reference Park SK, Lee WC, Lee DH, Mitnick CD, Han L, Seung KJ. Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea. Int J Tuberc Lung Dis. 2004;8(3):361–8.PubMed Park SK, Lee WC, Lee DH, Mitnick CD, Han L, Seung KJ. Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea. Int J Tuberc Lung Dis. 2004;8(3):361–8.PubMed
39.
go back to reference Burgos M, Gonzalez LC, Paz EA, Gournis E, Kawamura LM, Schecter G, Hopewell PC, Daley CL. Treatment of multidrug-resistant tuberculosis in San Francisco: an outpatient-based approach. Clin Infect Dis. 2005;40(7):968–75.CrossRefPubMed Burgos M, Gonzalez LC, Paz EA, Gournis E, Kawamura LM, Schecter G, Hopewell PC, Daley CL. Treatment of multidrug-resistant tuberculosis in San Francisco: an outpatient-based approach. Clin Infect Dis. 2005;40(7):968–75.CrossRefPubMed
40.
go back to reference Escudero E, Pena JM, Alvarez-Sala R, Vazquez JJ, Ortega A. Multidrug-resistant tuberculosis without HIV infection: success with individualised therapy. Int J Tuberc Lung Dis. 2006;10(4):409–14.PubMed Escudero E, Pena JM, Alvarez-Sala R, Vazquez JJ, Ortega A. Multidrug-resistant tuberculosis without HIV infection: success with individualised therapy. Int J Tuberc Lung Dis. 2006;10(4):409–14.PubMed
41.
43.
go back to reference Wu S, Zhang Y, Sun F, Chen M, Zhou L, Wang N, et al. Adverse events associated with the treatment of multidrug-resistant tuberculosis: a systematic review and meta-analysis. Am J Ther. 2013. Wu S, Zhang Y, Sun F, Chen M, Zhou L, Wang N, et al. Adverse events associated with the treatment of multidrug-resistant tuberculosis: a systematic review and meta-analysis. Am J Ther. 2013.
Metadata
Title
The effect of surgery on the outcome of treatment for multidrug-resistant tuberculosis: a systematic review and meta-analysis
Authors
Rebecca C. Harris
Mishal S. Khan
Laura J. Martin
Victoria Allen
David A. J. Moore
Katherine Fielding
Louis Grandjean
the LSHTM MDR-TB surgery systematic review group
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2016
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-016-1585-0

Other articles of this Issue 1/2016

BMC Infectious Diseases 1/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine